Dexcom Inc. Aktie
70,18 €
Deine Einschätzung
Dexcom Inc. Aktie
Was spricht für und gegen Dexcom Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Dexcom Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Dexcom Inc. | 0,63 % | 1,40 % | -3,13 % | 7,84 % | -7,05 % | -17,25 % | -22,47 % |
Henry Schein Inc. | 1,29 % | 1,78 % | -3,32 % | -5,20 % | -10,97 % | -22,12 % | 5,94 % |
Teleflex Inc. | -0,94 % | 2,94 % | 8,25 % | -50,93 % | -37,50 % | -55,51 % | -65,91 % |
Baxter International | 1,90 % | 1,28 % | -10,59 % | -36,28 % | -24,78 % | -65,13 % | -70,28 % |
Kommentare
News

2 Stocks to Buy on the Dip and Hold for 10 Years
Despite President Donald Trump's trade wars and concerns about a possible recession, equity markets have performed relatively well this year, with the S&P 500 (SNPINDEX: ^GSPC) up 10% since January

DexCom (DXCM) Q2 Revenue Jumps 15%
DexCom (NASDAQ:DXCM) reported its second-quarter 2025 results on July 30, 2025, delivering an upbeat performance highlighted by a revenue beat and continued expansion in the key type 2 diabetes

Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights:
-
Revenue grew 15% year-over-year to